依维莫司联合减量钙调磷酸酶抑制剂在肾移植中的疗效与安全性
这项多中心非劣效性试验将2037例新发肾移植受者随机分配至依维莫司联合减量CNI组或MPA联合标准剂量CNI组。主要终点(12个月时经治疗的活检证实的急性排斥或eGFR<50 ml/min/1.73m²)发生率分别为48.2%和45.1%,差异3.2%(95%CI -1.3%至7.6%),符合非劣效性。依维莫司组CMV和BK病毒感染率更低,但因不良事件停药率更高。
要点
- 依维莫司联合减量CNI在主要复合终点上非劣效于MPA联合标准CNI。
- 依维莫司组CMV感染(3.6% vs 13.3%)和BK病毒感染(4.3% vs 8.0%)发生率更低。
- 依维莫司组因不良事件停药率更高(23.0% vs 11.9%)。
核心结论
- 在轻至中度免疫风险的肾移植受者中,依维莫司联合减量CNI在评估免疫抑制疗效和移植物功能保护的二分类复合终点上非劣效于MPA联合标准CNI。
研究设计与样本
- 多中心非劣效性试验,随机分配2037例新发肾移植受者接受依维莫司联合减量CNI(n=1022)或MPA联合标准剂量CNI(n=1015),均联合诱导治疗和糖皮质激素,非劣效性界值为10%。
主要发现
- 在意向治疗人群中,主要终点(经治疗的活检证实的急性排斥或eGFR<50 ml/min/1.73m²)发生率依维莫司组为48.2%(493例),MPA组为45.1%(457例),差异3.2%(95%CI -1.3%至7.6%)。
- 12个月时经治疗的活检证实的急性排斥、移植物丢失或死亡发生率依维莫司组为14.9%,MPA组为12.5%,差异2.3%(95%CI -1.7%至6.4%)。
- 12个月时新生供体特异性抗体发生率和抗体介导的排斥反应率两组间无差异。
- 巨细胞病毒感染率依维莫司组为3.6%,MPA组为13.3%;BK病毒感染率依维莫司组为4.3%,MPA组为8.0%。
- 因不良事件停止研究药物的患者比例依维莫司组为23.0%,MPA组为11.9%。
临床怎么用
- 对于轻至中度免疫风险的肾移植受者,可考虑使用依维莫司联合减量CNI作为MPA联合标准CNI的替代方案,但需注意不良事件导致的停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combination with induction therapy and corticosteroids, everolimus with reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) with standard-exposure CNI (MPA arm). The primary end point was treated biopsy-proven acute rejection or eGFR<50 ml/min per 1.73 m2 at post-transplant month 12 using a 10% noninferiority margin.Results In the intent-to-treat population (everolimus n=1022, MPA n=1015), the primary end point incidence was 48.2% (493) with everolimus and 45.1% (457) with MPA (difference 3.2%; 95% confidence interval, -1.3% to 7.6%). Similar between-treatment differences in incidence were observed in the subgroups of patients who received tacrolimus or cyclosporine. Treated biopsy-proven acute rejection, graft loss, or death at post-transplant month 12 occurred in 14.9% and 12.5% of patients treated with everolimus and MPA, respectively (difference 2.3%; 95% confidence interval, -1.7% to 6.4%). De novo donor-specific antibody incidence at 12 months and antibody-mediated rejection rate did not differ between arms. Cytomegalovirus (3.6% versus 13.3%) and BK virus infections (4.3% versus 8.0%) were less frequent in the everolimus arm than in the MPA arm. Overall, 23.0% and 11.9% of patients treated with everolimus and MPA, respectively, discontinued the study drug because of adverse events.Conclusions In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was noninferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.
引用
- Pascual J, Berger SP, Witzke O, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018. PMID: 29752413. doi:10.1681/ASN.2018010009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。